Latest Strategy News

True North Copper reported significant copper-gold and copper-cobalt-silver discoveries in its September 2025 quarter, reinforcing its growth strategy and financial strength heading into 2026.

Stakk Limited reports a staggering 1,836% year-on-year increase in quarterly receipts, positioning itself on track to hit an $8 million annual recurring revenue target by mid-2026.

Cadoux Limited has made significant progress in its High Purity Alumina (HPA) front-end engineering design and advanced the Minhub rare earths feasibility study, positioning itself strongly in the evolving critical minerals market.

American West Metals reports robust drilling results at its Storm Copper Project in Canada and renews momentum at its West Desert Project in Utah, supported by a $7 million capital raise to advance critical metals development.

Eureka Group Holdings reports a transformative year marked by a 29% increase in rental units, a landmark acquisition in Perth, and a strong development pipeline, setting the stage for significant earnings growth in FY26.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

Citigold Corporation continues its efforts to restart the high-grade Charters Towers Gold Project, focusing on exploration, mine design, and securing funding despite a significant annual loss.

Terra Critical Minerals (ASX, T92) broadens its critical minerals portfolio with new US initiatives and promising exploration in New South Wales and Canada. The company also pursues a US OTC listing to tap North American capital.

Vulcan Steel reported a sharp profit decline in FY25 amid tough market conditions but strengthened its balance sheet and expanded into roofing with a major acquisition. Leadership changes set the stage for renewed growth.

International Graphite Limited has made significant strides in its global graphite strategy, signing a German joint venture and securing $3 million in US institutional funding to support its expanding mine-to-market operations.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

The Star Entertainment Group reported a 5% revenue increase in Q1 FY26 and a halving of its EBITDA loss, while navigating regulatory challenges and advancing a major joint venture exit.